AXSM Axsome Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development, commercialization, and sales of pharmaceutical products for CNS disorders, including AUVELITY, SUNOSI, and launch of SYMBRAVO in 2025
• • New product: Commercial launch of SYMBRAVO began June 2025, generating $6.6 million in net sales for the year, no sales in prior year
• • Strategic shift: Expanded commercial focus from AUVELITY and SUNOSI to include SYMBRAVO, increasing total revenues 65.6% YoY to $638.5 million in 2025
• • Quantitative metric: Net sales growth – AUVELITY sales up 74% to $507.1 million; SUNOSI up 33% to $120.1 million, total revenue increase from $385.7 million to $638.5 million
• • Noteworthy fact: Recorded a significant decrease in net loss, $183.2 million in 2025 vs $287.2 million in 2024, reflecting scaling commercialization efforts

Risk Factors

• • Regulatory risk: FDA Breakthrough Therapy designation for AXS-05 for AD agitation may not expedite approval or guarantee marketing authorization
• • Geopolitical risk: EU sanctions on Russia extended to July 31, 2026, with potential supply chain and capital market disruptions impacting operations
• • Supply chain risk: Dependence on third-party manufacturers subject to regulatory compliance and volume fulfillment could delay product commercialization
• • Market disruption risk: Competition from other pharma, biotech firms, government agencies, and research organizations may impair operating results
• • Financial risk: $570M Blackstone loan with restrictive covenants and minimum $30M liquidity may limit operational flexibility and risk default

What are the latest AXSM SEC filings in 2026?

Axsome Therapeutics, Inc. (AXSM) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on July 15, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AXSM file its most recent 10-K annual report?

Axsome Therapeutics, Inc. (AXSM) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AXSM 10-Q quarterly reports?

Axsome Therapeutics, Inc. (AXSM)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every AXSM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AXSM filed recently?

Axsome Therapeutics, Inc. (AXSM)'s most recent 8-K was filed on July 15, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AXSM insider trading activity (Form 4)?

SignalX aggregates every AXSM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AXSM file with the SEC?

Axsome Therapeutics, Inc. (AXSM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AXSM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Axsome Therapeutics, Inc. (AXSM).

What is AXSM's SEC CIK number?

Axsome Therapeutics, Inc. (AXSM)'s SEC CIK (Central Index Key) number is 1579428. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1579428 to look up all AXSM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AXSM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Axsome Therapeutics, Inc. (AXSM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.